French Construction Stock News

Investors may be asking whether Air France KLM at €8.75 is starting to look like value, or if the risks still outweigh the potential upside. The stock is down 5.6% over the last week and 28.9% over the past month, while the 1 year return is 2.5%. These moves come as investors reassess airline stocks in general, with sentiment often swinging quickly on changes in travel demand, fuel costs, and regulatory signals. For Air France KLM, this context helps explain why the share price can react...

Eurazeo (ENXTPA:RF) has been removed from the FTSE All-World Index. The change affects the stock’s presence in a major global equity benchmark tracked by index funds and ETFs. This type of index action can influence trading activity and how institutional investors view the company. Eurazeo is a listed investment company with exposure to private equity style assets, which means its share often sits on the radar of global fund managers. Being dropped from a widely followed index such as the...

Why Elis is on investors’ radar today Elis (ENXTPA:ELIS) has drawn attention after recent share price pressure, with the stock down about 11% over the past month and slightly lower over the past 3 months. This has prompted fresh interest in its valuation. See our latest analysis for Elis. Despite the recent 11% 30 day share price decline and softer short term momentum, Elis still carries a 1 year total shareholder return of about 20% and an approximately 84% total shareholder return over 5...

Investors were underwhelmed by the solid earnings posted by SergeFerrari Group SA ( EPA:SEFER ) recently. We have done...

The market for Capgemini SE's ( EPA:CAP ) shares didn't move much after it posted weak earnings recently. We think that...

One of the biggest stories of last week was how STIF Société anonyme ( EPA:ALSTI ) shares plunged 26% in the week since...

As the European markets navigate through uncertainties spurred by geopolitical tensions and energy price fluctuations, investor sentiment remains cautious yet discerning. In such a climate, growth companies with high insider ownership often stand out as potentially resilient investments due to the alignment of interests between insiders and shareholders, which can be particularly advantageous during periods of economic volatility.

Today is shaping up negative for 2CRSI S.A. ( EPA:AL2SI ) shareholders, with the analysts delivering a substantial...

Bolloré (ENXTPA:BOL) has drawn fresh attention after its board proposed an exceptional €1.5 per share dividend, about €4.2b, alongside 2025 results and a regular €0.08 per share dividend plan. See our latest analysis for Bolloré. The exceptional dividend proposal and 2025 earnings release have arrived after a mixed period, with a 3.96% three month share price return, a 1.17% year to date share price gain, but a 1 year total shareholder return decline of 11.46%, suggesting short term momentum...

Sanofi received FDA Breakthrough Therapy designation for oral venglustat targeting neurological symptoms in type 3 Gaucher disease. Sanofi reported positive phase 3 results for amlitelimab in atopic dermatitis. European regulators issued a positive opinion for Sarclisa subcutaneous with an on body injector for multiple myeloma, potentially introducing dual administration modes in the EU. Sanofi, traded as ENXTPA:SAN, is currently priced at €81.99 and has seen a 5.4% gain over the past week,...

If you are wondering whether ABIVAX Société Anonyme is priced attractively right now, the starting point is to compare what you pay today with what the business could be worth under different valuation lenses. The stock last closed at €89.20, after a 7 day return of an 18.5% decline and a 30 day return of a 13.1% decline, set against a very large 1 year gain and an 11.8x return over 3 years. Recent attention on ABIVAX Société Anonyme has been shaped by ongoing coverage of its position in the...

Ipsen (ENXTPA:IPN) has come into focus after presenting fresh preclinical data at the AACR congress for two first in class oncology candidates, IPN01203 and IPN60300, targeting difficult solid tumor indications. See our latest analysis for Ipsen. The latest oncology data and recent conference activity come at a time when Ipsen’s share price has reached €157.7, with recent momentum reflected in a 90 day share price return of 32.97% and a 1 year total shareholder return of 48.68%. This...

Thales has partnered with the Dominican Republic to launch the country's first electronic passport, integrating advanced cybersecurity for citizen data. The project establishes a secure e-passport system and ongoing cyber threat monitoring for the Dominican Republic's border and identity infrastructure. For investors tracking ENXTPA:HO, this agreement adds additional real world evidence of Thales' role in digital identity and security, alongside its existing defense and aerospace...

Investors in Innate Pharma S.A. ( EPA:IPH ) had a good week, as its shares rose 2.4% to close at €1.10 following the...

It's been a pretty great week for Netgem SA ( EPA:ALNTG ) shareholders, with its shares surging 11% to €0.76 in the...

Wondering whether EssilorLuxottica Société anonyme is starting to look attractively priced, or if the recent share price leaves little margin for error. The stock last closed at €194.80, with returns of 0.0% over 7 days, a 17.8% decline over 30 days, a 26.6% decline year to date, and a 25.8% decline over 1 year, set against gains of 23.8% over 3 years and 52.1% over 5 years. Recent moves in the share price sit against a backdrop of ongoing interest in the business and its role in the global...

How Accor’s Recent Share Performance Frames Today’s Setup Accor (ENXTPA:AC) has seen its share price fall about 17% over the past month and about 15% over the past 3 months, putting the hotel group’s current valuation and fundamentals back in focus for investors. See our latest analysis for Accor. That recent 17% 1 month share price decline sits against a 1 year total shareholder return of about a 3% decline and a 3 year total shareholder return of about 48%. This suggests shorter term...

Before getting into the numbers, it helps to know why Thales might be on your radar, especially if you are asking whether the current share price still represents value or if most of the opportunity is already reflected in the market. Recently, Thales shares closed at €237.90, with returns of 1.2% year to date, 85.1% over 3 years and 203.1% over 5 years. Over the last 7 days and 30 days the shares showed declines of 1.8% and 6.1% respectively, which can shift how investors think about both...

DBV Technologies (ENXTPA:DBV) has put fresh numbers on the table for FY 2025, with third quarter revenue of US$2.8 million and a basic EPS loss of US$0.24 alongside a net income loss of US$33.2 million. Together, these figures provide a clear snapshot of where the business stands today. Over recent quarters, the company has reported revenue of US$0.5 million in Q4 2024, US$0.8 million in Q1 2025, US$1.5 million in Q2 2025 and US$2.8 million in Q3 2025. Over the same period, quarterly EPS has...

Valeo (ENXTPA:FR) is investing $225 million in a new manufacturing facility in Texas. The plant will produce central compute units for General Motors' software-defined vehicles. The project supports one of the largest orders in Valeo's history and expands its US footprint. For investors watching the auto technology space, this move places Valeo more firmly among the suppliers building the electronics behind software-defined vehicles. The Texas facility connects directly to Valeo's existing...

Dassault Aviation société anonyme (ENXTPA:AM) has drawn investor attention after recent trading left the shares around €310, with mixed returns, including a decline over the past month and gains over the past 3 months and longer periods. See our latest analysis for Dassault Aviation société anonyme. At a share price of €310, Dassault Aviation société anonyme has recently given back some ground, with a 30 day share price return of a 9.88% decline. This comes even though the 90 day share price...

If you are wondering whether Dassault Systèmes at €16.61 is starting to look like value, you are not alone. This article is designed to help you frame that question clearly. The stock has seen a 3.5% decline over the last 7 days, a 7.9% decline over the last 30 days, a 29.0% decline year to date, and a 53.7% decline over the last year, with a 55.3% decline over 3 years and 54.5% decline over 5 years. These sustained declines have put valuation firmly in focus for many investors, who are...

Sanofi (ENXTPA:SAN) is back in focus after Japan approved Dupixent for adults with moderate to severe bullous pemphigoid, a rare skin disease. This adds another immunology indication to its portfolio. See our latest analysis for Sanofi. News around Dupixent and other rare disease programs has coincided with a short-term lift, with a 1-day share price return of 1.36% and 7-day share price return of 3.84%, although the 1-year total shareholder return of 16.82% and 3-year total shareholder...

If you are wondering whether BNP Paribas at €81.87 offers fair value or a potential bargain, this article explores what the current price might imply for you as a shareholder. The stock has recently seen mixed returns, with a 3.1% decline over 7 days and a 13.3% decline over 30 days, while still showing 13.1% over 1 year, 88.7% over 3 years, and 122.1% over 5 years. Recent headlines around BNP Paribas have focused on its position as a major European bank in a sector where investors are...